Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2007-01-23
2007-01-23
Lambkin, Deborah C. (Department: 1626)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C549S068000
Reexamination Certificate
active
10491710
ABSTRACT:
The present invention provides novel compounds and methods for using them to treat diseases with aminothiophene inhibitors of IKK-β phosphorylation of IκB. In so doing these aminothiophene inhibitors block pathological activation of transcription factor NF-κB in which diseases excessive activation of NF-κB is implicated.
REFERENCES:
patent: 3963750 (1976-06-01), Goudie
patent: 5422335 (1995-06-01), Hagen et al.
patent: 6143777 (2000-11-01), Jonas et al.
patent: 6274590 (2001-08-01), Talley et al.
patent: 6414013 (2002-07-01), Fancelli et al.
patent: 6835745 (2004-12-01), Coghlan et al.
patent: 6881735 (2005-04-01), Schindler et al.
patent: 6881741 (2005-04-01), Chan Chun Kong et al.
patent: 7019027 (2006-03-01), Linden et al.
patent: 7084178 (2006-08-01), Marcin et al.
patent: 7098240 (2006-08-01), Griffiths et al.
patent: WO 01/58890 (2001-08-01), None
patent: WO 02/30353 (2002-04-01), None
Burgess Joelle L.
Callahan James F.
Wan Zehong
Kellerman James C.
Lambkin Deborah C.
Lemanowicz John L.
Madden Laura K.
SmithKline Beecham Corporation
LandOfFree
NF-κB inhibitors does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with NF-κB inhibitors, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and NF-κB inhibitors will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3727325